Epithalon (molecular formula C14H22N4O9, monoisotopic molecular weight 390.35 Da) is a synthetic ultrashort linear tetrapeptide with the primary sequence: L-alanyl-L-alpha-glutamyl-L-alpha-aspartyl-glycine (Ala-Glu-Asp-Gly, AEDG). Its small molecular size permits rapid cellular uptake and nuclear translocation without specialized membrane transporters.

In mortal human somatic cell lines that constitutively lack active telomerase (such as fetal lung and skin fibroblasts), Khavinson et al. (Bull Exp Biol Med 2003) demonstrated that epithalon treatment directly initiates de novo transcription of the catalytic subunit of human telomerase reverse transcriptase (hTERT). Quantitative real-time PCR revealed an 8-to-12-fold increase in hTERT mRNA transcripts within 48 hours of incubation.

Chromatin immunoprecipitation (ChIP) and electrophoretic mobility shift assays (EMSA) indicate that the AEDG tetrapeptide interacts directly with specific unmethylated promoter regions on the hTERT gene, altering histone acetylation and relaxing nucleosomal compaction, which permits RNA polymerase II assembly and catalytic telomerase holoenzyme reconstitution.

Using the Telomeric Repeat Amplification Protocol (TRAP), researchers confirmed that epithalon-induced hTERT mRNA translates into catalytically active telomerase ribonucleoprotein complexes capable of adding TTAGGG hexanucleotide repeats to the 3' single-stranded overhangs of human chromosomes.

Southern blot terminal restriction fragment (TRF) analysis showed that epithalon treatment stabilized and elongated telomere length from an initial senescent baseline of 5.8 kb back to 8.2 kb, enabling an additional 10 to 12 population doublings past the canonical Hayflick limit.

Crucially, extensive cytogenetic and karyotypic profiling confirmed that this proliferative expansion occurs with zero chromosomal aneuploidy, translocations, or oncogenic transformation. Telomerase induction by epithalon is strictly self-limiting and does not induce the immortalized malignant phenotype characteristic of oncogene transfection.

In aging mammals, progressive pineal involution, calcification, and loss of pinealocyte sensitivity result in blunted circadian melatonin secretion, leading to fragmented sleep architecture, impaired immune surveillance, and accelerated systemic senescence.

Anisimov et al. (Biogerontology 2003) demonstrated that administration of epithalon to aged rodents restored nocturnal melatonin synthesis to levels characteristic of young animals, accompanied by histological restoration of pinealocyte cytoplasmic density and secretagogue granule formation.

Concurrently, epithalon upregulates endogenous antioxidant enzyme transcription in pineal, hepatic, and cerebral tissues—markedly elevating copper-zinc superoxide dismutase (Cu/Zn-SOD) and glutathione peroxidase (GPx) activities, effectively quenching mitochondrial reactive oxygen species (ROS) and preserving cellular membrane fluidity.

Over 15 independent long-term geroprotective trials conducted in female Swiss mice, CBA mice, and Wistar rats demonstrated that regular intermittent administration of epithalon extended mean lifespan by 12% to 17% and prolonged maximum lifespan by up to 28% compared to control cohorts.

Importantly, unlike caloric restriction or growth factor manipulations that sometimes compromise immunocompetence, epithalon-treated animals exhibited a 30% to 50% reduction in the spontaneous development of age-associated malignant tumors (such as mammary adenocarcinomas and leukemias).

The antitumorigenic mechanism is attributed to improved T-cell functional differentiation, enhanced natural killer (NK) cell cytotoxicity, and preserved genomic stability through ongoing DNA excision repair.

Epithalon is supplied as a white lyophilized solid powder. Molecular weight is 390.35 Da. Because it is an ultrashort tetrapeptide, it dissolves almost instantly in water with minimal hydrodynamic drag.

Reconstitution protocol: for a standard 10.0 mg vial, adding 2.0 mL of Bacteriostatic Water USP (0.9% benzyl alcohol) yields a working solution of 5.0 mg/mL (5,000 mcg/mL). Adding 5.0 mL yields 2.0 mg/mL (2,000 mcg/mL).

Syringe calibration on a standard U-100 syringe (100 units = 1.0 mL; 1 unit = 0.01 mL = 50 mcg epithalon at 5 mg/mL): a common research dose of 1.0 mg (1,000 mcg) corresponds to 20 units (0.20 mL); a 5.0 mg dose corresponds to 100 units (1.0 mL). At 2.0 mg/mL, 1.0 mg equals 50 units (0.50 mL).

Protocol cadence: In classic clinical research protocols, epithalon is typically investigated in 10-to-20 day pulse cycles (e.g., 5 to 10 mg daily for 10 consecutive days), repeated once or twice annually, reflecting its long-lasting epigenetic promoter activation window.

Storage: Solid lyophilate is stable at -20°C for up to 36 months, or 2°C–8°C for 24 months. Reconstituted solutions with 0.9% benzyl alcohol must be stored refrigerated at 2°C–8°C and protected from light, maintaining purity for 28 days.